Pasithea Therapeutics (KTTA) Notes Payables (2022 - 2023)
Pasithea Therapeutics (KTTA) posted Notes Payables of $4535.0 for Q2 2023, down 60.5% sequentially from $11481.0 in Q1 2023.
Pasithea Therapeutics (KTTA) Notes Payables (2022 - 2023) Analysis & Trends
Pasithea Therapeutics has reported Notes Payables for 2 years, with the latest figure at $4535.0 in Q2 2023.
- Quarterly Notes Payables changed N/A year-over-year to $4535.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $4535.0 (changed N/A YoY) and the FY2022 annual result came in at $8611.0, changed N/A from the prior year.
- Notes Payables declined to $4535.0 in Q2 2023 per KTTA's latest filing, from $11481.0 in the prior quarter.
- Over five years, Notes Payables peaked at $11481.0 in Q1 2023 and troughed at $4535.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4,535.00 |
| Mar 31, 2023 | 11,481.00 |
| Dec 31, 2022 | 8,611.00 |